That BRCA1 re-activation can be driven by alternative mechanisms in different BRCA1meth cancer tissues from a single patient, namely loss of BRCA1 methylation at the primary cancer site and a genomic rearrangement placing the BRCA1 gene under the control of a heterologous promoter in the metastasis to the liver, suggest that re-expression of BRCA1 is a significant driver for chemotherapeutic insensitivity. This evidence concerns the gene BRCA1 and cancer.